156 related articles for article (PubMed ID: 18793421)
1. MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells.
Robbins EW; Travanty EA; Yang K; Iczkowski KA
BMC Cancer; 2008 Sep; 8():260. PubMed ID: 18793421
[TBL] [Abstract][Full Text] [Related]
2. Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion.
Iczkowski KA; Omara-Opyene AL; Kulkarni TR; Pansara M; Shah GV
Anticancer Res; 2005; 25(3B):2075-83. PubMed ID: 16158948
[TBL] [Abstract][Full Text] [Related]
3. The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression.
Iczkowski KA; Omara-Opyene AL; Shah GV
Anticancer Res; 2006; 26(4B):2863-72. PubMed ID: 16886606
[TBL] [Abstract][Full Text] [Related]
4. TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.
Chen Q; Gu M; Cai ZK; Zhao H; Sun SC; Liu C; Zhan M; Chen YB; Wang Z
Cell Mol Life Sci; 2021 Feb; 78(3):949-962. PubMed ID: 32440711
[TBL] [Abstract][Full Text] [Related]
5. Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.
Yang K; Tang Y; Habermehl GK; Iczkowski KA
BMC Cancer; 2010 Jan; 10():16. PubMed ID: 20074368
[TBL] [Abstract][Full Text] [Related]
6. Cell adhesion molecule CD44: its functional roles in prostate cancer.
Iczkowski KA
Am J Transl Res; 2010 Sep; 3(1):1-7. PubMed ID: 21139802
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of mitogen-activated protein kinase is inhibited by calcitonin in DU145 prostate cancer cells.
Segawa N; Nakamura M; Nakamura Y; Mori I; Katsuoka Y; Kakudo K
Cancer Res; 2001 Aug; 61(16):6060-3. PubMed ID: 11507054
[TBL] [Abstract][Full Text] [Related]
8. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy.
Kallakury BV; Yang F; Figge J; Smith KE; Kausik SJ; Tacy NJ; Fisher HA; Kaufman R; Figge H; Ross JS
Cancer; 1996 Oct; 78(7):1461-9. PubMed ID: 8839552
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level.
Iczkowski KA; Bai S; Pantazis CG
Anticancer Res; 2003; 23(4):3129-40. PubMed ID: 12926045
[TBL] [Abstract][Full Text] [Related]
10. Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression.
Yang K; Tang Y; Iczkowski KA
Am J Transl Res; 2010 Jan; 2(1):88-94. PubMed ID: 20182585
[TBL] [Abstract][Full Text] [Related]
11. Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action.
Sabbisetti VS; Chirugupati S; Thomas S; Vaidya KS; Reardon D; Chiriva-Internati M; Iczkowski KA; Shah GV
Int J Cancer; 2005 Nov; 117(4):551-60. PubMed ID: 15929083
[TBL] [Abstract][Full Text] [Related]
12. Silibinin suppresses CD44 expression in prostate cancer cells.
Handorean AM; Yang K; Robbins EW; Flaig TW; Iczkowski KA
Am J Transl Res; 2009 Jan; 1(1):80-6. PubMed ID: 19966941
[TBL] [Abstract][Full Text] [Related]
13. Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing.
Zeng Y; Wodzenski D; Gao D; Shiraishi T; Terada N; Li Y; Vander Griend DJ; Luo J; Kong C; Getzenberg RH; Kulkarni P
Cancer Res; 2013 Jul; 73(13):4123-33. PubMed ID: 23667174
[TBL] [Abstract][Full Text] [Related]
14. The CD44 standard isoform contributes to radioresistance of pancreatic cancer cells.
Tsubouchi K; Minami K; Hayashi N; Yokoyama Y; Mori S; Yamamoto H; Koizumi M
J Radiat Res; 2017 Nov; 58(6):816-826. PubMed ID: 29106581
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor.
Thomas S; Chigurupati S; Anbalagan M; Shah G
Mol Endocrinol; 2006 Aug; 20(8):1894-911. PubMed ID: 16574742
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of CD44 expression by lipopolysaccharide (LPS) and TNF-alpha in human monocytic cells: distinct involvement of c-Jun N-terminal kinase in LPS-induced CD44 expression.
Gee K; Lim W; Ma W; Nandan D; Diaz-Mitoma F; Kozlowski M; Kumar A
J Immunol; 2002 Nov; 169(10):5660-72. PubMed ID: 12421945
[TBL] [Abstract][Full Text] [Related]
17. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway.
Weg-Remers S; Ponta H; Herrlich P; König H
EMBO J; 2001 Aug; 20(15):4194-203. PubMed ID: 11483522
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18.
Omara-Opyene AL; Qiu J; Shah GV; Iczkowski KA
Lab Invest; 2004 Jul; 84(7):894-907. PubMed ID: 15107804
[TBL] [Abstract][Full Text] [Related]
20. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion.
Gaiteiro C; Soares J; Relvas-Santos M; Peixoto A; Ferreira D; Paulo P; Brandão A; Fernandes E; Azevedo R; Palmeira C; Freitas R; Miranda A; Osório H; Prieto J; Lima L; Silva AMN; Santos LL; Ferreira JA
Theranostics; 2022; 12(7):3150-3177. PubMed ID: 35547758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
